SCHEMBL4089765

SCHEMBL4089765

O=C1CCCN1CCOc1cc(-c2nc(Cl)nc3[nH]cnc23)c(Cl)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HSP90AB1 P08238 4/20 0.38
KCNH2 Q12809 1/20 0.38
BRD4 O60885 1/20 0.37
SGK1 O00141 2/20 0.36
CTSS P25774 3/20 0.36
CTSK P43235 1/20 0.35
POLB P06746 2/20 0.35
PDK2 Q15119 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
GFER P55789 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HSP90AA1 P07900 1/20 0.33
PGK1 P00558 1/20 0.33
EGFR P00533 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4094713 0.84 HSP90AB1 (0.51) HSP90AB1KCNH2KDM4EHSP90AA1
SCHEMBL14567387 0.79 MEN1 (0.38) IDH1MEN1KMT2AHSP90AB1KCNH2
SCHEMBL4097355 0.74 YTHDC1 (0.42) IDH1MEN1KMT2AHSP90AB1CTSS
SCHEMBL4098709 0.74 HSP90AB1 (0.44) HSP90AB1KCNH2KDM4EALDH1A1HSP90AA1
SCHEMBL4091000 0.73 HSP90AB1 (0.51) HSP90AB1KCNH2KDM4EHSP90AA1EGFR
SCHEMBL14567388 0.73 IDH1 (0.41) IDH1KMT2AKDM4EALDH1A1MAPT
SCHEMBL4084482 0.71 L3MBTL1 (0.41) CTSSKDM4EALDH1A1EGFR
SCHEMBL2562485 0.68 HSP90AB1 (0.64) IDH1HSP90AB1KCNH2HSP90AA1
SCHEMBL4094869 0.67 HSP90AB1 (0.46) HSP90AB1KCNH2POLBKDM4EALDH1A1
SCHEMBL4101361 0.66 CCR5 (0.37) HSP90AB1KCNH2HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
EP-2004648-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER Vernalis (R&D) Limited (GB) 2008-12-24 EP disclosed
WO-2007034185-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER VERNALIS (R & D) LTD. (GB) 2007-03-29 WO disclosed
WO-2007034185-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER VERNALIS (R & D) LTD. (GB) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer HSP90AA1, HSP90AB1, HSP90AB2P IDH1 71/4885MEN1 3720/4885KMT2A 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.